-+ 0.00%
-+ 0.00%
-+ 0.00%

AnaptysBio FY27 Q1 income from continuing operations drops 93% year over year to $3.88 million

PUBT·11/12/2026 21:34:25
Listen to the news
AnaptysBio FY27 Q1 income from continuing operations drops 93% year over year to $3.88 million
  • AnaptysBio's net income fell 74% year over year to $3.88 million for the fiscal first quarter ended September 30, 2026.
  • Collaboration revenue dropped 60% year over year to $30.27 million, primarily due to $50 million in milestone revenue recognized a year earlier.
  • A judgment in litigation against GSK and Tesaro is expected in calendar Q4 2026 or Q1 2027; AnaptysBio seeks Jemperli rights reversion.
  • Quimilza's FDA target action date for generalized pustular psoriasis is December 12, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AnaptysBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611121615PRIMZONEFULLFEED9876709) on November 12, 2026, and is solely responsible for the information contained therein.